New Inversion Regs Won't Hinder $16.6B Johnson-Tyco Tie-Up
The newly unveiled anti-tax inversion regulations that thwarted Pfizer Inc.'s plan to combine with Irish drugmaker Allergan PLC earlier this month will not do the same for Johnson Controls Inc.'s $16.6...To view the full article, register now.
Already a subscriber? Click here to view full article